Cancer associated thrombosis (CAT) including venous and arterial thromboembolism (VTE and ATE respectively), as well as subclinical hypercoagulable states pose a risk of serious morbidity and mortality and poor outcomes in cancer patients. It is increasingly clear that rather than being unspecific aftermaths of tumour growth, CAT is causally linked to the molecular phenotype of cancer cells and its genetic and epigenetic oncogenic drivers. Emerging data suggest that mutational events and factors modifying chromatin architecture in cancer cells influence the repertoire of genes (coagulome) the products of which may interact with the hemostatic system either directly or through modification of inflammatory system or release of cancer-related prothrombotic extracellular vesicles (EVs). Single cell transcriptomic analysis of brain tumours reveals the coexistence of multiple coagulant mechanisms associated with different cancer cell subpopulations and sites. These observations may suggest that a multipronged, biologically based approach may be needed to effectively predict and manage CAT.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.beha.2022.101349DOI Listing

Publication Analysis

Top Keywords

cancer cells
8
cancer
6
blood coagulation
4
coagulation cancer
4
cancer genes
4
genes cancer
4
cancer associated
4
associated thrombosis
4
thrombosis cat
4
cat including
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!